Our website is made possible by displaying non-intrusive online advertisements to our visitors.
Please consider supporting us by disabling or pausing your ad blocker.
Duopharma’s strong market position in the generic drug sector offers steady long-term growth, but current valuations look a bit pricey for the modest earnings recovery. You need to wait for a better entry point because the margins are quite tight given the intense competition in the pharmaceutical space.
DPHARMA really got solid potential with their healthcare focus and strong growth prospects in the long run. Steady demand for medicine confirm keep them profitable, so just steady lah and hold for the future gains.
